Daratumumab and Recombinant Human Hyaluronidase
Sponsors
National Cancer Institute (NCI), Roswell Park Cancer Institute, Eden Biltibo
Conditions
Multiple MyelomaPlasma Cell LeukemiaRecurrent Multiple MyelomaRefractory Multiple Myeloma
Phase 1
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
RecruitingNCT06622005
Start: 2025-04-10End: 2030-04-10Target: 15Updated: 2026-04-21
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
WithdrawnNCT07082270
Start: 2026-04-01End: 2028-02-01Updated: 2026-05-15
Phase 2
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
Active, not recruitingNCT06169215
Start: 2024-07-23End: 2026-09-30Target: 70Updated: 2026-07-08
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
Not yet recruitingNCT06948084
Start: 2026-08-26End: 2028-02-28Target: 80Updated: 2026-05-13
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
Not yet recruitingNCT07485647
Start: 2026-05-01End: 2029-04-01Target: 50Updated: 2026-03-20
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
Not yet recruitingNCT07605416
Start: 2026-07-29End: 2032-11-06Target: 74Updated: 2026-07-06